FIELD: chemistry.
SUBSTANCE: invention relates to a compound having the formula VIIb:
VIIb,
wherein each of R1 and R2 is hydrogen; R3 is hydrogen or C1-6alkyl; each Q1 independently is halogen, oxo, C1-6alkyl, -RuORx, -RuSRx, =NORd, where alkyl groups are optionally substituted with one hydroxyl; Y is -(CR5R6)q-; Z is O or S; each W is independently CR8 or N; W1 is N or C; W2 is N or C; W4 is N; W5 is N or CR13; R13 is hydrogen or Q2; each of Q5 and Q6 independently represents hydrogen, halogen, cyano, C1-6alkyl, halogen C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkenyl, 5-6 membered heteroaryl with one to four nitrogen atoms, 6-membered heterocyclyl with one to two heteroatoms independently selected from a nitrogen atom and oxygen, 6-membered partially unsaturated heterocyclyl with one heteroatom selected from a nitrogen atom and oxygen, (6-membered heterocyclyl with two heteroatoms independently selected from nitrogen atom and oxygen)-C1-6alkyl, -RuORx, -RuN(Ry)(Rz), -RuSRx, -RuC(J)Rx, -RuC(J)ORx, -RuC(J)N(Ry)(Rz), -RuC(J)C1-6alkyl-N(Ry)(Rz), -RuC(J)N(Ry)ORx, -RuS(O)tRw, -RuN(Rx)C(J)Rx or -C(=NORx)Rx, where the alkyl, alkenyl, alkynyl, heteroaryl and heterocyclyl groups are optionally substituted with one to three Q groups8; J is O or NRx; each t is 2; and q is 0 or 1; values of other radicals are given in the patent claim. Invention also relates to pharmaceutical composition, to method for treating a disease and to a method for modulating a kinase CSF1R, FLT3, KIT and/or PDGFRβ.
EFFECT: technical result: new compounds of formula VIIb, which are kinase modulators CSF1R, FLT3, KIT and/or PDGFRβ.
20 cl, 6 dwg, 4 tbl, 242 ex
Title | Year | Author | Number |
---|---|---|---|
BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
NOVEL COMPOUNDS OF CONDENSED HETEROCYCLYL-CARBOHYDRAZONOYL DICYANIDES AND USE THEREOF | 2021 |
|
RU2826002C1 |
BENZOTHIAZOLE COMPOUNDS AND METHODS FOR THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 2018 |
|
RU2778370C2 |
COMPOUNDS FOR THE TREATMENT OF CERTAIN LEUKOSIS | 2019 |
|
RU2804709C2 |
PHENICOL ANTIBACTERIAL AGENTS | 2013 |
|
RU2593204C2 |
CONDENSED DERIVATIVES OF IMIDAZOLE AND PYRAZOLE AS MODULATORS OF ACTIVITY TNF | 2014 |
|
RU2686117C1 |
ANILIDES OF AMINO ACIDS AS LOW-MOLECULAR MODULATORS IL-17 | 2019 |
|
RU2815505C2 |
COMPOUNDS, COMPOSITIONS AND METHODS FOR CFTR MODULATION | 2016 |
|
RU2752567C2 |
COMPOUNDS OF PYRIDAZINAMIDE AND THEIR USE AS SYNTHETIC SYNECKINASIS INHIBITORS (SYK) | 2013 |
|
RU2627661C2 |
Authors
Dates
2018-03-29—Published
2012-10-12—Filed